Hjem › Neuroendokrine tumorer › Ohio
Neuroendokrine tumorer kliniske forsøg i Ohio
14 studier for Neuroendokrine tumorer søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- University Hospitals Cleveland Medical Center, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT06943755A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- Investigative Site, Canton
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06881992Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererFase 1
24 Months – 18 Years · Alle køn · Opdateret 25. sep. 2026 · NCT06441331EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT06263088Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
- University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT07087054Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- Research Facility, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT07165132Project: Every Child for Younger Patients With Cancer
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- og 5 flere
RekruttererObservationsstudie
Op til 25 år · Alle køn · Opdateret 25. aug. 2026 · NCT02402244Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 19 til 110 · Alle køn · Opdateret 29. jun. 2026 · NCT02012699A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- The Ohio State University Wexner Medical Center, Columbus
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 27. maj 2026 · NCT03093116Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- UH Cleveland Medical Center, Cleveland
- Ohio State University, Columbus
RekruttererFase 1/2
Alder 18 til 90 · Alle køn · Opdateret 14. maj 2026 · NCT05636618Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- Research Facility, Columbus
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. mar. 2026 · NCT05477576A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 11. dec. 2025 · NCT06943521SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- Case Comprehensive Cancer Center, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2025 · NCT06805825Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.